SOUTH SAN FRANCISCO, Calif., June 23, 2025 - CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) announced the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of its lead compound, CER-1236. The trial, titled "Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia (CertainT-1)," is designed to assess the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia. Preliminary results from the trial's Dose Escalation Safety Committee indicate that the first patient demonstrated no dose-limiting toxicity during the 28-day observation period. The company plans to dose a second patient in the cohort shortly. CERo has announced plans to initiate a second trial of CER-1236 in solid tumors later this year. Further updates on the trial's progress will be provided in the future.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。